Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study

Rachael Williams*, Frank de Vries, Wolfgang Kothny, Carmen Serban, Sandra Lopez-Leon, Changan Chu, Raymond Schlienger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

103 Downloads (Pure)


The aim of this non-interventional, multi-database, analytical cohort study was to assess the cardiovascular (CV) safety of vildagliptin vs other non-insulin antidiabetic drugs (NIADs) using real-world data from 5 European electronic healthcare databases. Patients with type 2 diabetes aged >= 18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for the outcomes of interest (myocardial infarction [MI], acute coronary syndrome [ACS], stroke, congestive heart failure [CHF], individually and as a composite) were estimated using negative binomial regression. Approximately 2.8% of the enrolled patients (n = 738 054) used vildagliptin at any time during the study, with an average followup time of 1.4 years, resulting in a cumulative current vildagliptin exposure of 28 330 person-years. The adjusted IRRs (vildagliptin [+other NIADs] vs other NIADs) were in the range of 0.61 to 0.97 (MI), 0.55 to 1.60 (ACS), 0.02 to 0.77 (stroke), 0.49 to 1.03 (CHF), and 0.22 to 1.02 (composite CV outcomes). The IRRs and their 95% CIs were close to 1, demonstrating no increased risk of adverse CV events, including the risk of CHF, with vildagliptin vs other NIADs in real-world conditions.

Original languageEnglish
Pages (from-to)1473-1478
Number of pages6
JournalDiabetes Obesity & Metabolism
Issue number10
Publication statusPublished - Oct 2017


  • cardiovascular disease
  • DPP-4 inhibitor
  • observational study
  • type 2 diabetes
  • vildagliptin

Cite this